Navigation Links
Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
Date:10/13/2009

Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group's business is subject to the risk factors outlined in its registration documents filed with the French Autorite des Marches Financiers.

[1] depending on the countries, Ipsen commercialises Decapeptyl(R) under different brand names (Diphereline(R), Pamorelin(R), Arvekap(R))

    [2] triptorelin pamoate is similar to triptorelin embonate

    For further information:

    Ipsen

    Media

    Didier Veron
    Director, Public Affairs and Corporate Communications
    Tel.: +33-(0)1-58-33-51-16
    Fax:  +33-(0)1-58-33-50-58
    E-mail: didier.veron@ipsen.com

    Financial Community

    David Schilansky
    Investor Relations and Financial Officer
    Tel.: +33-(0)1-58-33-51-30
    Fax:  +33-(0)1-58-33-50-63
    E-mail: david.schilansky@ipsen.com

    Pierre Kemula
    Investor Relations Manager
    Tel.: +33-(0)1-58-33-60-08
    Fax:  +33-(0)1-58-33-50-63
    E-mail: pierre.kemula@ipsen.com

    Debiopharm

    Debiopharm S.A. Contact
    Maurice Wagner
    Director Corporate Affairs &
    Communication
    Tel.: +41-(0)21-321-01-11
    Fax:  +41-(0)21-321-01-69
  
'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
2. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
3. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
4. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
5. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
6. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Japanese Cancer Association and Debiopharm Honour Japanese Research
9. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
10. Debiopharm and EPFL Establish an Oncology Chair
11. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... to materialise. Yet, scientists are making progress in ... One such approach relies on quantum dotsa kind ... electric field. A new study demonstrates that changing ... (TQDs) with electrical impulses can help better control ... be used as quantum information units, which would ...
(Date:7/24/2014)... Research and Markets has announced ... Analytical Instruments Market 2014-2018" report to their offering. ... Genomics is the study of the gene and its ... and functions of proteomes or sets of proteins by ... involves the mapping of genes and DNA sequencing to ...
(Date:7/24/2014)... 24, 2014 Three companies from the ... Livestrong’s Big C Competition. Out of 700 competition entrants, ... to the semi-final round. In this round twenty teams ... program, complete with mentoring from thought-leaders and medical entrepreneurs ... of the angelMD commitment to the Livestrong vision around ...
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... knowingly misrepresented the ... company to ... filed a,proposed class-action lawsuit on behalf of CellCyte Genetics Corporation,(OTC ... and chief executive officer Gary A.,Reys, background, causing company stocks ...
... SAN DIEGO, Jan. 18 The San Diego ... has received the,highest score in three of four ... on Part I of the Major Facilities Grant,Application., ... earned scores of,99 for basic research and discovery, ...
... objects to implications in a New York Times article ... clinical,trials., The story, based on a separate article ... and Lilly as high-profile examples of how the,industry purportedly ... story inaccurate when it comes to Prozac -- the ...
Cached Biology Technology:Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application 2SDCRM Receives Highest Score in Three of Four Categories from CIRM on Part I of Major Facilities Grant Application 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 4
(Date:7/25/2014)... New research at the University of Adelaide has opened the ... resistance to powdery mildew. , In Australia, annual barley production ... year. Powdery mildew is one of the most important diseases ... team have discovered the composition of special growths on the ... the fungus into the leaf. , The research, by the ...
(Date:7/25/2014)... central nervous system disease that is caused by ... the embryonic phase. Many patients have varying degrees ... retardation. Such problems decrease the patients, functional independence ... Physical Medicine and Rehabilitation Education and Research Hospital, ... SB, using the Pediatric Evaluation of Disability Inventory ...
(Date:7/25/2014)... that the age girls reach puberty is influenced by ,imprinted ... parent contributes the gene. This is the first evidence ... birth and details of this study were published today in ... period, known as menarche, is a marker for the timing ... onset of menses varies between girls, is an inherited trait, ...
Breaking Biology News(10 mins):New hope for powdery mildew resistant barley 2Could age of first period influence development of diseases in older women? 2
... provide key insights for scientists and medical researchers, but ... pose some key challenges. Researchers at North Carolina ... the parameters used in such models which may ... fertility. "These oscillatory systems are found in everything ...
... facility in the US, researchers at the University of Gothenburg have ... is to film how proteins work at molecular level. ... cells could be the key to cures for everything from cancer ... University of Gothenburg, and his research group were among the first ...
... Carrying a gun in bear country doesn,t mean you,re more protected ... out of Brigham Young University. A study led by BYU ... gun is no more effective in keeping people from injury or ... really isn,t about the kind of gun you carry, it,s about ...
Cached Biology News:New method for estimating parameters may boost biological models 2New method for estimating parameters may boost biological models 3More effective method of imaging proteins 2BYU study: Using a gun in bear encounters doesn't make you safer 2
... Versatile, modular, computer controlled pre-amplifier suitable for ... isolated electrode input for recording physiological signal ... and a transducer input for use with ... transducers. Additional options include a stimulus artefact ...
... Polystyrene covers can be used ... Ridged covers for stacking of ... covers for use with automated ... ridged and non-ridged, are available ...
... available for use with 96- or 384-well PCR plates ... ease of location on 96-tube plates End tabs ... of the plate* Efficient sealing is achieved with ... with screw or clip-down hot lid thermal cyclers ...
... be used with all 96-well ... stacking of covered plates ... with automated systems ... are available for use with ...
Biology Products: